期刊文献+

吡喹酮-硬脂酸固体脂质纳米粒的制备及性能评价 被引量:2

Preparation and performance evaluation of praziquantel-octadecanoic acid solid lipid nanoparticles
原文传递
导出
摘要 目的:制备吡喹酮-固体脂质纳米粒,考察其理化性质和体外释放度。方法:以硬脂酸为脂质材料,聚乙烯吡咯烷酮为乳化剂,利用热熔乳化超声法制备吡喹酮-固体脂质纳米粒,扫描电镜观察纳米粒形态和均匀度,纳米粒度仪测定其粒径、分散指数、Zeta电位、包封率和载药量,并进行体外释放试验。结果:制备的固体脂质纳米粒为类圆球状,粒径分布较均匀、表面光滑。纳米的平均粒径、分散指数、电位、包封率和载药量分别为(316.5±22.8)nm、0.23±0.05、(-25.3±0.7)mV,(92.64±5.12)%和(18.45±1.34)%。药物在制剂的过程中稳定性良好。体外释放表明吡喹酮-硬脂酸固体脂质纳米粒在生理盐水中具有一定程度的突释和显著的缓释效果。结论:本试验制备的吡喹酮-硬脂酸固体脂质纳米粒具有较好的均匀度和高载药量,并具有良好的缓释性能。 OBJECTIVE To prepare praziquantel-loaded octadecanoic acid-solid lipid nanoparticles(PZQ-SLN).METHODS PZQ-SLN was prepared by a hot homogenization and ultrasonication method using octadecanoic acid,polyvinyl pyrrolidoneas matrix and surfactant.Selection of lipid and emulsifier,and optimization of preparation parameter were studied.Morphology was examined by transmission electron microscope.Particle size,entrapment efficiency and zeta potential were determined,and drug release profiles of PZQ SLN were investigated.Stability of PZQ during preparation was also studied.RESULTS Morphological investigation showed that nanoparticles had round and uniform shapes.Encapsulation efficiency,loading capacity,diameter,polydispersity index and zeta potential of praziquantel-SLN were(92.64±5.12)%,(18.45±1.34)%,(316.5±22.8)nm,0.23±0.05 and(-25.3±0.7)mV,respectively.In vitro release studies demonstrated that SLN exhibited an initial burst release followed by a sustained release.The drug was stable during preparation.CONCLUSION Lipophilic praziquantel-loaded SLN is successfully developed and the results indicate that SLN may be a promising delivery system to enhance therapeutic effects and prolong systemic circulation of praziquantel.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2016年第14期1180-1184,共5页 Chinese Journal of Hospital Pharmacy
关键词 吡喹酮 固体脂质纳米粒 硬脂酸 热熔乳化超声 制备 praziquantel solid lipid nanopartieles octadecanoic acid hot homogenization and ultrasonication preparation
  • 相关文献

参考文献17

  • 1DansAppiah A, De VLAS S J. Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal[J].Trends in Parasitology, 2002, 18(3): 125-129.
  • 2Doenhoff MJ, Kusel JR, Cole GC, et al. Resistance of Schis- tosoma mansoni to praziquantel: is there a problem? [J]. Transaction of the Royal Society of Tropical Medicine& Hy- giene, 2002, 96: 465-469.
  • 3Cioli D. Praziquantel: is there real resistance and are there al- ternatives? [J]. Current Opinion in Infectious Diseases, 2000, 13(6) : 659-663.
  • 4Nayak AK, Dhara AK. Nanotechnology in drug delivery ap- plieations:A review[J]. Applied Scientific Research, 2010, 2 (2) : 284-293.
  • 5Krause HJ, Schwarz A, Rohdewald P. Polylactic acid nanop- articles,a colloidal drug delivery system for lipophilic drugs [J]. International Journal of Pharmaceutics, 1985, 27(2/3): 145 -155.
  • 6HU Liandong, TANG Xlng, CUI Fude. Solid lipid nanoparti- cles (SLNs) to improve oral bioavailability of poorly soluble drugs[J]. The Journal of Pharmacy and Pharmacology, 2004, 56(12) :11527-1535.
  • 7Mohapatra S, Mallick SK, Maiti TK, et al. Synthesis of highly stable folic acid conjugated magnetite nanoparticles for targeting cancer cells [J]. Nanotechnology, 2007, 18 (38): 510-512.
  • 8Mehnert W, Mader K. Solid lipid nanoparticles - Production, characterization and applications[J]. Advanced Drug Delivery Reviews, 2001, 47(2/3): 165-196.
  • 9Almeida AJ, Souto E. Solid lipid nanoparticles as a drug deliv- ery system for peptides and proteins[J]. Advanced Drug Deliv- ery Reviews, 2007, 59(6): 478-490.
  • 10姚健康,钟拥军.固体脂质纳米粒的研究进展[J].医药导报,2005,24(11):1031-1032. 被引量:2

二级参考文献16

  • 1毛世瑞,王燕芝,纪宏宇,毕殿洲.微乳化技术制备固体脂质纳米粒[J].药学学报,2003,38(8):624-626. 被引量:38
  • 2曾振灵,陈杖榴,冯淇辉.吡喹酮在猪体内的生物利用度及药物动力学研究[J].畜牧兽医学报,1993,24(2):170-174. 被引量:10
  • 3洪慧,龙晓英,李力任,林丹,梁少华.葡聚糖微型凝胶柱测定辣椒碱柔性脂质体包封率的条件探讨[J].广东药学院学报,2005,21(2):120-123. 被引量:29
  • 4侯冬枝,谢长生,平其能.表面活性剂复配制备稳定的固体脂质纳米粒混悬液(英文)[J].中国药科大学学报,2005,36(5):417-422. 被引量:17
  • 5Zara G P, Cavalli R, Bargoni A, et al. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent :pharmacokinetics and distribution of doxorubicin in brain and other tissues[ J ]. J Drug Target ,2002,10 (4) :327 - 335.
  • 6Dimirel M, Yazan Y, Muller R H, et al. Formulation and in vitro-in vivo evaluation of pifibedil solid lipid micro-and nanoparticles[J]. J Microencapsul, 2001,18 ( 3 ) : 359 - 371.
  • 7Muller R H, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug deliver-a review of the art [ J ]. Eur J Pharm Biopharm ,2000,50( 1 ) : 161 - 177.
  • 8Jenning V,Gysler A, Schaferkorting M,et al. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin [ J ]. Eur J Pharm Biopharm, 2000,49(3) :211 -218.
  • 9Cavalli R , Caputo O, Gasco M R. Solid lipid nanoparticles of doxorubicin and idarubicin[ J]. lnt J Pharm,1993 ,89 :9 -12.
  • 10Perkins W R, Abmad I, Li X, et al. Novel therapeutic nanoparticles (lipocores) : trapping poorly water soluble compounds [J]. lnt J Pharm, 2000,200:27 - 39.

共引文献8

同被引文献19

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部